FRANKFURT, Aug. 9 (Reuters) – BioNTech and its partner Pfizer (PFE.N) have provided more than a billion doses of their COVID-19 vaccine as of July 21, a number higher than that delivered by competitor AstraZeneca (AZN. L), the German biotechnology group said Monday.
The supply tally, up from more than 700 million doses announced by the biotech company in June, compares to AstraZeneca which said late last month that it and its manufacturing partner Serum Institute of India had supplied one billion doses to 170 countries at the time. Read more
Based on delivery contracts for more than 2.2 billion doses to date, BioNTech said in a statement that it expects to generate 15.9 billion euros ($ 18.7 billion) from revenue from the vaccine this year, up from a forecast of 12.4 billion euros in May. Read more
This includes sales, partner milestone payments and a share of gross profit in partner territories, the company added.
At the end of last month, Pfizer raised its forecast for its share of 2021 vaccine sales to $ 33.5 billion. Read more
BioNTech added on Monday that it and Pfizer believe that a third dose, following the established two-shot regimen, “has the potential to preserve the highest levels of protective efficacy against all variants currently being tested, including Delta.” , highlighting similar remarks made by his partner. .
Still, he reiterated his intention to begin testing a vaccine suitable for the highly infectious Delta variant of the virus on humans this month, as part of a “comprehensive strategy to combat the variants, if the need arises. ‘felt it in the future “.
($ 1 = 0.8509 euros)
Reporting by Ludwig Burger Editing by Caroline Copley, Douglas Busvine and Chizu Nomiyama
Our standards: Thomson Reuters Trust Principles.